{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:16:50Z","timestamp":1792588610846,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejphar.2023.176113","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T02:07:14Z","timestamp":1697076434000},"page":"176113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPAR\u03b3\/CD36 pathway and altering the gut microbiota"],"prefix":"10.1016","volume":"960","author":[{"given":"Jing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176113_bib1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/hep.31417","article-title":"Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults","volume":"73","author":"Alferink","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176113_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155233","article-title":"GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease","volume":"133","author":"Baumann","year":"2022","journal-title":"Metab., Clin. Exp."},{"key":"10.1016\/j.ejphar.2023.176113_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(01)00066-6","article-title":"Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones","volume":"35","author":"Bedoucha","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","article-title":"Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease","volume":"34","author":"Byrne","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2023.176113_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: high-resolution sample inference from Illumina amplicon data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejphar.2023.176113_bib7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ejphar.2023.176113_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176113_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ismej.2013.155","article-title":"High-fat diet alters gut microbiota physiology in mice","volume":"8","author":"Daniel","year":"2014","journal-title":"ISME J."},{"key":"10.1016\/j.ejphar.2023.176113_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-nutr-072610-145146","article-title":"Interaction between obesity and the gut microbiota: relevance in nutrition","volume":"31","author":"Delzenne","year":"2011","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ejphar.2023.176113_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03263-19","article-title":"Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease","volume":"11","author":"Fei","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ejphar.2023.176113_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1208\/s12248-016-9919-9","article-title":"Dual outcomes of rosiglitazone treatment on fatty liver","volume":"18","author":"Gao","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2023.176113_bib14","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176113_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","article-title":"A human hepatocellular in vitro model to investigate steatosis","volume":"165","author":"G\u00f3mez-Lech\u00f3n","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2023.176113_bib16","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1096\/fj.201902687R","article-title":"Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis","volume":"34","author":"Gupta","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2023.176113_bib17","first-page":"227","article-title":"Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases","volume":"9","author":"Hern\u00e1ndez-Ceballos","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1039\/C8FO02364F","article-title":"Anti-inflammation effects of fucosylated chondroitin sulphate from Acaudina molpadioides by altering gut microbiota in obese mice","volume":"10","author":"Hu","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.ejphar.2023.176113_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmet.2012.05.012","article-title":"Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling","volume":"16","author":"Imajo","year":"2012","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2023.176113_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.176113_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176113_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176113_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236353","article-title":"Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development","volume":"15","author":"Kriss","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176113_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jcmgh.2021.01.003","article-title":"Hepatocyte-specific loss of PPAR\u03b3 protects mice from NASH and increases the therapeutic effects of rosiglitazone in the liver","volume":"11","author":"Lee","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ejphar.2023.176113_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176113_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.ejphar.2023.176113_bib27","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1210\/endo.141.11.7771","volume":"141","author":"Memon","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2023.176113_bib28","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","article-title":"Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease","volume":"20","author":"Miura","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.176113_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib30","doi-asserted-by":"crossref","first-page":"G911","DOI":"10.1152\/ajpgi.00225.2013","article-title":"Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model","volume":"305","author":"Okubo","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2023.176113_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/dom.13628","article-title":"Development of in vitro three-dimensional co-culture system for metabolic syndrome therapeutic agents","volume":"21","author":"Park","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.176113_bib32","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1210\/jc.2010-2129","article-title":"Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction","volume":"96","author":"Pettinelli","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.176113_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","article-title":"Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators","volume":"16","author":"Piccinin","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176113_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176113_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.176113_bib36","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1073\/pnas.95.13.7614","article-title":"Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein","volume":"95","author":"Ricote","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176113_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2023.176113_bib38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3748\/wjg.v21.i5.1414","article-title":"Association between Helicobacter spp. infections and hepatobiliary malignancies: a review","volume":"21","author":"Segura-L\u00f3pez","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.176113_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0092-8674(00)81575-5","article-title":"PPARgamma promotes monocyte\/macrophage differentiation and uptake of oxidized LDL","volume":"93","author":"Tontonoz","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2023.176113_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"\\\"J. Adv. Pharm. Technol. Research\\\"\\\" (JAPTR)\\\""},{"key":"10.1016\/j.ejphar.2023.176113_bib41","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR gamma gene expression by nutrition and obesity in rodents","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.176113_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phrs.2016.02.028","article-title":"PPAR\u03b3 signaling and emerging opportunities for improved therapeutics","volume":"111","author":"Wang","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2023.176113_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115051","article-title":"The anti-fibrotic efficacy of adelmidrol depends on hepatic PPAR\u03b3 levels","volume":"165","author":"Xiang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.176113_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2023.176113_bib45","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176113_bib46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1074\/jbc.M210062200","article-title":"Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression","volume":"278","author":"Yu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176113_bib47","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/09298673113209990136","article-title":"Hepatic PPARs: their role in liver physiology, fibrosis and treatment","volume":"20","author":"Zardi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176113_bib48","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fmicb.2019.01595","article-title":"Cecropin A alleviates inflammation through modulating the gut microbiota of C57bl\/6 mice with DSS-induced IBD","volume":"10","author":"Zhai","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2023.176113_bib49","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/srep07375","article-title":"Protopanaxatriol, a novel PPAR\u03b3 antagonist from Panax ginseng, alleviates steatosis in mice","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176113_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8917993","article-title":"The study of Yin-chen-Hao-Tang preventing and treating alcoholic fatty liver disease through PPAR signaling pathway based on network pharmacology and RNA-seq transcriptomics","volume":"2021","author":"Zhu","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:25:41Z","timestamp":1762143941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923006271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":50,"alternative-id":["S0014299923006271"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176113","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPAR\u03b3\/CD36 pathway and altering the gut microbiota","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176113"}}